Investors & Media

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
– Designation offers potential for expedited development and review, and highlights the urgent need for additional treatment options for patients suffering from depression – – Sage has received two Breakthrough Therapy designations for separate psychiatric drug candidates, reinforcing the Company’s
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders
– SAGE-217 met primary endpoint of improved sleep efficiency and demonstrated improvements in maintaining sleep compared to placebo – – Secondary endpoint measures demonstrated clear dose response with statistical significance in total sleep time and time spent awake after sleep onset – – Data
View HTML
Toggle Summary Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company
– Company evolving, as planned, to be a leading, innovative CNS company – – 2018 strategy focuses on continued R&D innovation, pipeline expansion and commercialization plans for new classes of CNS therapeutics – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company is scheduled to present at the J.P.
View HTML
Toggle Summary Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 7, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at
View HTML
Toggle Summary Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder
– SAGE-217 met primary endpoint and provided rapid, profound and durable effects through 2-week treatment period and additional 4-week follow-up – – Well-tolerated and demonstrated highly statistically significant mean reduction in the HAM-D score compared to placebo at 15 days (p
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 1, 2017 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 17, 2017-- Sage Therapeutics  (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public
View HTML